<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981653</url>
  </required_header>
  <id_info>
    <org_study_id>ANNOTEP</org_study_id>
    <nct_id>NCT03981653</nct_id>
  </id_info>
  <brief_title>ANgiogenic Function at NOrmal TErm on Placenta</brief_title>
  <acronym>ANNOTEP</acronym>
  <official_title>Angiogenic Function at Normal Term on Placenta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vivo and ex vivo study of trophoblastic angiogenic trophoblastic function in placentas
      from normal pregnancies, at term
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to better understand the regulation of trophoblast expression
      of pro- and antiangiogenic factors such as placenta growth factor (PlGF) or Soluble FMS like
      tyrosin-kinase-1 (sFlt-1), and more particularly on human differentiated trophoblastic cells
      from &quot;healthy&quot; placentas. The measurement of the variation in gene and protein expression of
      placental angiogenic factors will provide a better understanding of their pathophysiology.

      Secondary objectives are the study of trophoblastic differentiation and placental functions,
      and the study of the impact of chemical compounds on the biological functions of the
      placenta. To do this, these &quot;healthy&quot; placentas may be exposed to different factors that
      promote the occurrence of specific pregnancy pathologies such as pre-eclampsia and vascular
      intrauterine growth restriction (IUGR), caused by placental dysfunction. This will make it
      possible to test molecules and vector approaches targeted directly at the trophoblast, in
      order to consider therapeutic targets, which do not exist to date.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">March 2029</completion_date>
  <primary_completion_date type="Anticipated">March 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of placental angiogenic factors</measure>
    <time_frame>day 0</time_frame>
    <description>Variation in the gene and protein expression of placental angiogenic factors on healthy placentas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of sFlt-1 (Soluble FMS like tyrosin-kinase-1)</measure>
    <time_frame>day 1</time_frame>
    <description>Sflt-1 levels when the placenta is exposed to factors that promote the development of vascular pregnancy diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of PlGF (Placental Growth Factor)</measure>
    <time_frame>day 1</time_frame>
    <description>PlGF levels when the placenta is exposed to factors that promote the development of vascular pregnancy diseases</description>
  </secondary_outcome>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Pregnancy Related</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a progressive, full-term pregnancy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnancies with scheduled cesarean delivery &gt;37 weeks of amenorrhea:

          -  strictly normal pregnancies

          -  complicated pregnancies of gestational diabetes, insulin-treated or not

          -  complicated pregnancies due to pregnancy cholestasis

          -  spontaneous or in vitro fecondation (IVF) / Intracytoplasmic sperm injection (ICSI)
             pregnancies with or without oocyte donation

        Exclusion Criteria:

          -  Patient's opposition

          -  Age &lt; 18 years old

          -  Women under the protection of justice

          -  Multiple pregnancy

          -  Known major fetal malformation

          -  Pre-eclampsia and intrauterine growth retardation

          -  Placental insertionnomaly

          -  Type 1 diabetes

          -  HIV-positive patient with HIV/hepatisis C virus (HCV) regardless of viral load

          -  Patient in labour at the time of Caesarean section

          -  Patient whose medical history results in medication being taken in pregnancy courses
             that may interfere with the biology of the trophoblast (immunomodulators in case of
             autoimmune diseases, anti-rejection drugs in case of transplant patients)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>camille JUNG, MD</last_name>
    <phone>00157022268</phone>
    <email>camille.jung@chicreteil.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lecarpentier Edouard, MD</last_name>
      <phone>00145175543</phone>
      <email>edouard.lecarpentier@chicreteil.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

